ASPIRE has signed a letter to Congressman Schrader and Congressman Kinzinger to support the BIOSIM Act. This act would accelerate patient access to new biosimilar treatments by providing a temporary increase to physician reimbursement. Under Medicare Part B, biosimilars are currently reimbursed at the average sales price (ASP) +6%. The BIOSIM Act would increase biosimilar reimbursement by two percent to ASP+8%. Importantly, the policy only applies when a biosimilar’s price is lower than the price of the brand-name reference biologic. This guarantees savings to Medicare and reduces out-of-pocket costs for seniors. For these reasons, we, the undersigned organizations, are pleased to endorse the BIOSIM Act.
We are proud to support the #BIOSIMAct along with about 2 dozen other healthcare leaders. This important legislation guarantees savings to Medicare and reduces out-of-pocket costs by streamlining #biosimilars into the U.S. marketplace.
- 60 Plus Association
- Advocacy & Awareness for Immune Disorders Association
- Allergy & Asthma Network
- Alliance for Aging Research Alliance for Retired Americans
- Alliance to Solve PANS & Immune-Related Encephalopathies (ASPIRE)
- American Consumer InstituteBlack Women’s Health Imperative
- CancerCare Center for Freedom and Prosperity
- Consumer ActionDallas-Fort Worth Business Group on Health
- Endocrine SocietyHealthy
- Women Hypertrophic Cardiomyopathy Association
- International Pemphigus and Pemphigoid Foundation
- Lupus Foundation of America
- Men’s Health Network National Center & Caucus on Black Aging
- National Consumers League
- Patients Rising Now
- R Street
- Institute Rheumatology
- Nurses Society
- Scleroderma Foundation
- Sister’s Network, Inc.
- Sjögren’s Foundation
- Texas Business Group on Health
- The Mended Hearts, Inc
Gabriella True
